Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates
Open accessThe DOI matches its Crossref record.
Abstract
GFR from serum creatinine–based equations informs medication management in CKD. These equations include age, sex, and race (Black versus non-Black), and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation increases eGFR by approximately 16% for Black persons.1 This has led to concern about systematically different care; however, removal of the race factor has led to concern about medication eligibility and dosing.1 Glucose-lowering medication recommendations in CKD depend on eGFR. The Kidney Disease Improving Global Outcomes (KDIGO) Guideline for Diabetes Management in CKD recommends medication classes for CKD.2 Metformin is the first-line medication for type 2 diabetes in general, yet has a lower eGFR threshold (30 ml/min per 1.73 m2). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1ras) have shown kidney and cardiovascular benefits and are preferred in CKD.2 However, the KDIGO guideline outlines lower eGFR limits for initiation (30 ml/min per 1.73 m2 for SGLT2i and 15 ml/min per 1.73 m2 for GLP-1ra).2 Removal of the race coefficient from eGFR for Black persons means some would newly qualify for CKD-preferred medications (eGFR reduced into CKD range) and some would no longer qualify (eGFR reduced below thresholds). We estimated the proportion of Black adults in the United States with type 2 diabetes for whom medication recommendations could be affected by dropping the eGFR race coefficient. We used the National Health and Nutrition Examination Survey (NHANES), a study that enables estimates of the United States population. NHANES was approved by the National Center for Health Statistics institutional review board. We combined four 2-year data cycles, 2011–2018, adjusted the weights and applied survey methods to estimate cross-sectional totals and proportions of the population.3 We included persons aged ≥20 years with self-reported Black race and type 2 diabetes. GFR estimates used CKD-EPI, and CKD was classified using eGFR and albuminuria.4 We further classified by metformin, SGLT2i, and GLP-1ra recommendations from the KDIGO diabetes guideline.2 For those reclassified as having CKD when the race coefficient was omitted, we estimated the proportion with prior indication for SGLT2i or a GLP-1ra based on the American Diabetes Association guideline (for cardiovascular disease or weight loss). Multiple imputation was performed for missing laboratory data (Supplemental References). We identified 923 observations, representing a cross-sectional estimate of 4,007,966 (95% confidence interval [95% CI], 3,358,243 to 4,657,689) Black adults with type 2 diabetes (Supplemental Table 1). Using race-based eGFR and albuminuria classification, 39.3% (95% CI, 36.2% to 42.4%) were classified as having CKD. This increased to 45.2% (95% CI, 41.9% to 48.5%) using eGFR without the race coefficient. This was an additional 5.9% (95% CI, 4.4% to 7.3%) of the study population classified with CKD—an estimated 235,341 (95% CI, 158,920 to 311,762) individuals. SGLT2i initiation (by the CKD guideline) would be recommended for 35.3% (95% CI, 32.4% to 38.2%) of Black persons with diabetes under race-based GFR estimation, versus 40.3% (95% CI, 37.4% to 43.2%) using eGFR without the race coefficient. GFR without race coefficient would reclassify 0.8% (95% CI, 0.1% to 1.4%) of Black persons with diabetes <30 ml/min per 1.73 m2, too low for SGLT2i initiation or metformin continuation, and 0.3% (95% CI, 0.0% to 0.7%) would drop <15 ml/min per 1.73 m2, too low for GLP-1ra. Of those newly classified with CKD, 27.8% (95% CI, 15.0% to 40.6%) would qualify for SGLT2i or GLP-1ra for cardiovascular indications, and 93.4% (95% CI, 86.0% to 100%) would qualify for weight loss (body mass index >25 kg/m2). Figure 1 presents results in a visual format.Figure 1.: Estimated proportions of Black adults with type 2 diabetes in the US, categorized by CKD status. (A) Tree map representing Black adults with type 2 diabetes in the United States categorized by KDIGO CKD group with eGFR estimated without race coefficient. The areas of the colored rectangles are proportional to the estimated number in each group. The bracket labeled “CKD” identifies the groups that would be considered to have CKD on the basis of eGFR and albuminuria (all groups except the green rectangle). The bright rectangles (with asterisks) represent proportions that undergo CKD classification into a more severe CKD group that could influence diabetes treatment when eGFR is calculated without race coefficient (versus eGFR with race coefficient). (B) Groups undergoing reclassification into a relevant higher CKD stage (eGFR calculated without versus with race coefficient) are highlighted here (same groups and scale as in (A)). Classifications use the KDIGO CKD classification on the basis of eGFR (G1/G2: ≥60 ml/min per 1.73 m2; G3a: 45–59 ml/min per 1.73 m2; G3b: 30–44 ml/min per 1.73 m2; G4: 15–29 ml/min per 1.73 m2; G5:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.08.003 · Cited by 783
Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey-Mims, M. M., Roberts, G. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070988 · Cited by 423
Health inequities and the inappropriate use of race in nephrology
Eneanya, N. D., Boulware, L. E., Tsai, J., Bruce, M. A., Ford, C. L., Harris, C., Morales, L. S., Ryan, M. J., Reese, P. P., Thorpe, R. J., et al. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00501-8 · Cited by 140
Limited evidence for use of a black race modifier in eGFR calculations: a systematic review
Marzinke, M. A., Greene, D. N., Bossuyt, P. M., Chambliss, A. B., Cirrincione, L. R., McCudden, C. R., Melanson, S. E. F., Noguez, J. H., Patel, K., Radix, A. E., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvab279 · Cited by 19
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Metadata
- Authors
- Walther, C. P., Winkelmayer, W. C., & Navaneethan, S. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2021-06
- Volume
- 32
- Issue
- 6
- Pages
- 1319-1321
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W3140363855
- Cited by
- 13
- References
- 0
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates. https://app.cochat.ai/papers/10.1681/asn.2020121724
- The paper
- Walther, C. P., Winkelmayer, W. C., & Navaneethan, S. D. (2021). Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2020121724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.